Evidence map›Paper›PMID 37830484›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2023

Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects.

Sara Samadzadeh, Mads Nikolaj Olesen, Martin Wirenfeldt, Sören Möller, Tatsuro Misu, Kerstin Soelberg, Jette Lautrup Frederiksen, Steffen Heegaard, Sara Mariotto, Kazuo Fujihara and 13 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 15 institutions in 8 countries.

Sara SamadzadehDepartment of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Mads Nikolaj OlesenDepartment of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Martin WirenfeldtDepartment of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Sören MöllerOpen Patient Data Explorative Network, Odense University Hospital, University of Southern Denmark, Odense, Denmark.
Tatsuro MisuDepartment of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kerstin SoelbergDepartment of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Jette Lautrup FrederiksenDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, Glostrup, Denmark.
Steffen HeegaardDepartments of Ophthalmology and Pathology, Rigshospitalet, Glostrup, Denmark.
Sara MariottoNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
Kazuo FujiharaDepartment of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Fukushima, Japan.
Klemens RuprechtDepartment of Neurology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Thomas Levin AndersenDepartment of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Romain MarignierService de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.ORCID 0000-0002-5967-2800
Søren Thue LillevangDepartment of Clinical Immunology, Odense University Hospital, Odense, Denmark.
Eoin P FlanaganDepartment Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-6661-2910
Sean J PittockDepartment Neurology and Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8387-6491
Ho Jin KimDepartment of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Republic of Korea.ORCID 0000-0002-8672-8419
Jeffrey L BennettDepartment of Neurology & Ophthalmology, Programs in Neuroscience & Immunology University of Colorado, Anschutz, CO, USA.
Friedemann PaulExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Grith Lykke SorensenCancer and Inflammation, Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Brian G WeinshenkerDepartment of Neurology, University of Virginia, Charlottesville, VA, USA.
Hans LassmannCenter for Brain Research, Medical University of Vienna, Vienna, Austria.
Nasrin AsgariDepartment of Regional Health Research, University of Southern Denmark, Odense, Denmark.
University of Southern Denmark · DKMayo Clinic · USCopenhagen University Hospital · DKFukushima Medical University · JPHospices Civils de Lyon · FRHumboldt-Universität zu Berlin · DEMax Delbrück Center · DEMedical University of Vienna · ATNational Cancer Center · KROdense University Hospital · DKRigshospitalet · DKTohoku University · JPUniversity of Colorado Anschutz Medical Campus · USUniversity of Verona · ITUniversity of Virginia · US

Funding

Humoral Immunity, Astrocyte Injury, and Demyelination in Neuromyelitis OpticaR01EY022936 · NEI · UNIVERSITY OF COLORADO DENVER · PI BENNETT, JEFFREY L · 2013 to 2022
$3.8M
Utilizing epidemiology, imaging and fluid biomarkers in MOG antibody-associated disease to inform prognosis, pathogenesis and therapeuticsR01NS113828 · NINDS · MAYO CLINIC ROCHESTER · PI Eoin P Flanagan · 2020 to 2026
$2.4M
NEI NIH HHS R01 EY022936NINDS NIH HHS R01 NS113828
6 · The paper itself

Abstract

backgroundMicrofibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein not previously described in the human central nervous system (CNS).

objectivesWe determined MFAP4 CNS expression and measured cerebrospinal fluid (CSF) and serum levels.

methodsTissue was sampled at autopsy from patients with acute multiple sclerosis (MS) (

resultsMFAP4 localized to meninges and vascular/perivascular spaces, intense in the optic nerve. At sites of active inflammation, MFAP4 reactivity was reduced in NMOSD and acute MS and less in progressive MS. CSF MFAP4 levels were reduced during relapse and at the onset of diseases (mean U/mL: MS 14.3, MOGAD 9.7, and ION 14.6 relative to HC 17.9. (

conclusionMFAP4 immunoreactivity was reduced at sites of active inflammation. CSF levels of MFAP4 were reduced following relapse and may reflect disease activity.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveNeuromyelitis OpticaAquaporin 4AutoantibodiesCarrier ProteinsCentral Nervous SystemExtracellular Matrix ProteinsGlycoproteinsHumansInflammationMyelin-Oligodendrocyte GlycoproteinAquaporin 4AutoantibodiesCarrier ProteinsExtracellular Matrix ProteinsGlycoproteinsMFAP4 protein, humanMyelin-Oligodendrocyte Glycoproteincentral nervous systemInflammatory demyelinating diseasesmicrofibrillar-associated protein 4relapse

Identifiers

PMID37830484
PMCPMC10880047
OpenAlexW4387599852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.